

## **ACE2, the Counter-Regulatory Renin–Angiotensin System Axis and COVID-19 Severity**

Filippos Triposkiadis,<sup>1,\*</sup> Andrew Xanthopoulos,<sup>1</sup> Grigorios Giamouzis,<sup>1</sup> Konstantinos Dean Boudoulas,<sup>2</sup> Randall C. Starling,<sup>3</sup> John Skoularigis,<sup>1</sup> Harisios Boudoulas,<sup>2</sup> and Efstathios Iliodromitis<sup>4</sup>

Toshihiro Tsuruda, Academic Editor

Author information Article notes Copyright and License information Disclaimer

Copyright © 2021 by the authors.

***This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).***

**Clin Appl Thromb Hemost. 2020 Jan-Dec; 26: 1076029620943293.**

Published online 2020 Jul 31. doi: 10.1177/1076029620943293

PMCID: PMC7401047

PMID: 32735131

COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response

Apoorva Jayarangaiah, MD,<sup>1</sup> Pramod Theetha Kariyanna, MD,<sup>2</sup> Xiaoyi Chen, MD,<sup>3</sup> Amog Jayarangaiah, MD,<sup>4</sup> and Abhishek Kumar, MD<sup>1</sup>

Author information Article notes Copyright and License information Disclaimer

Copyright © The Author(s) 2020

***This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).***